Aykut Demirkiran

Dr. Aykut Demirkiran

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

22 September 2023 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
MKMustafa Korkmaz
Mustafa Korkmaz
MEMelek Karakurt Eryılmaz
Melek Karakurt Eryılmaz
MEmuhammed muhiddin er
muhammed muhiddin er
MKmehmet zahid Kocak
mehmet zahid Kocak
ADAykut Demirkiran
Aykut Demirkiran
ZKZahid Mehmet Koçak
Zahid Mehmet Koçak

31 January 2023 in Archives of Current Medical Research
Verified
Journal Article
Open access
PDF file
MKMustafa Korkmaz
Mustafa Korkmaz
MEMelek Karakurt Eryılmaz
Melek Karakurt Eryılmaz
MKmehmet zahid Kocak
mehmet zahid Kocak
ADAykut Demirkiran
Aykut Demirkiran
MAMurat Araz
Murat Araz
MAMehmet Artac
Mehmet Artac
Background: We aimed to investigate whether the HALP score is a prognostic marker in patients with recurrent GBM who were given bevacizumab plus irinotecan. Methods: We compared the survival of patients followed up in our clinic with the diagnosis of recurrent GBM and treated with bevacizumab plus irinotecan, according to HALP score. Results: Median PFS and OS were 4.5 (0.9-14.9) and 8 (0.9-21.3) months, respectively. The median PFS of the low HALP score group was 1.85 (1.3-3.37) months, and of the high HALP score group was 4.96 (0.9-14.9) months (p=0.03). The OS of the high HALP score group (9.63 [7.28-11.9]) was statistically higher compared with low HALP score group (2.26 [0.88-3.65]) (p

24 January 2025 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
MKmehmet zahid Kocak
mehmet zahid Kocak
MAMurat Araz
Murat Araz
SFSiddika Findik
Siddika Findik
ADAykut Demirkiran
Aykut Demirkiran
MKMustafa Korkmaz
Mustafa Korkmaz
MAMehmet Artac
Mehmet Artac
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast cancer (TNBC). Seventy patients were included in the study. Thirty-four patients were metastatic, and 36 patients were non-metastatic. CRELD2 protein expression in tumor tissue was determined by immunohistochemical staining (IHC). The patients were divided into two groups: CRELD2 positive and negative groups. Clinicopathological features and survival outcomes were compared between the groups. In the survival analysis of the non-metastatic patient group, five-year overall survival (OS) rate was 91.7% in the CRELD2-positive patient group and 91% in the negative group (P = 0.91). Median progression free survival (PFS) was 9.4 (95% confidence interval [CI]: 6.4–12.4) months in the CRELD2-positive group and 11.9 (95% CI: 8.2–18.6) months in the CRELD2-negative group (P = 0.04). The median OS was 17.2 (95% CI: 13.7–22.3) months in the CRELD2-positive group and 24.7 (95% CI: 21.8–29.6) months in the CRELD2-negative group (P = 0.02). In multivariate analysis, CRELD2 status (negative vs positive) (hazard ratio [HR]: 0.50, 95% CI: 0.38–0.96, P = 0.02) was determined to be a risk factor for OS and CRELD2 status (negative vs positive) (HR: 0.82, 95% CI: 0.33–0.96, P = 0.01) was defined as a risk factor for PFS in patients with metastatic TNBC. This is the first clinical study to determine the effect of CRELD2 on survival and as a prognostic marker in patients with triple metastatic breast cancer. These results need to be validated prospectively with a large sample size.

20 February 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ADAykut Demirkiran
Aykut Demirkiran
FKFahriye Kılınç
Fahriye Kılınç
MKMehmet Zahid Koçak
Mehmet Zahid Koçak
DDDeniz Demirkıran
Deniz Demirkıran
MKMustafa Korkmaz
Mustafa Korkmaz
MAMehmet Artaç
Mehmet Artaç

7 July 2022 in The Egyptian Journal of Otolaryngology
Verified
Journal Article
Open access
PDF file
MKMustafa Korkmaz
Mustafa Korkmaz
MEMelek Karakurt Eryılmaz
Melek Karakurt Eryılmaz
MKmehmet zahid Kocak
mehmet zahid Kocak
ADAykut Demirkiran
Aykut Demirkiran
MKMustafa Karaagac
Mustafa Karaagac
MAMehmet Artac
Mehmet Artac
Background: We aimed to investigate the effect of radiological complete response on survival outcomes in patients with non-metastatic nasopharyngeal cancer. This study is conducted as a retrospective cohort. Of the 185 patients screened, 60 were metastatic, 25 patients’ data was not available, and as a result, 92 patients were included in the study. Among the complete response (CR) and incomplete response (IR) groups, overall survival (OS), distant metastasis-free survival (DMFS), and locoregional failure-free survival (LRFFS) were evaluated. Results: Of the 92 patients, 54 (58.6%) were CR and 38 (41.4%) were IR patients. Of the whole study group, the 5-year OS, DMFS, and LRFFS rates were 75%, 78%, and 95%, respectively. A significant difference was found between the 5-year OS (90% vs. 60%, p = 0.001) and DMFS (87% vs. 65%, p = 0.02) rates. However, there was no significant difference in the 5-year LRFFS rate (97% vs. 92%, p = 0.16). Complete response were determined as an independent predictor for OS (HR: 0.13, 95% Cl: 0.045–0.36, p < 0.001) and DMFS (HR: 0.26, 95% CI: 0.095–0.744, p = 0.012). Conclusion: As a result, the survival benefit in patients with CR after primary treatment is evident as shown in the above studies. Therefore, the aim of primary treatment should be to increase the CR rates. It is important to evaluate early tumor response to determine poor tumor regression.